Fluoxymesterone (halotestin): interactions with alcohol and medications

Fluoxymesterone (halotestin) is rarely taken "in a vacuum". Alcohol, painkillers, anticoagulants, diabetes or acne medications, and other hormonal drugs are often present alongside it. Our editorial team has gathered the known and potential interactions — from those directly described in the drug’s package insert to those that follow from its pharmacology — and explains why a doctor should know about each of them.

Why halotestin’s interactions are especially important

Fluoxymesterone is a 17α-methylated oral androgen. This structure lets it pass through the liver when taken by mouth, but at the same time it makes the liver the main "target" of possible toxicity. Any substance that additionally burdens the liver potentially amplifies this risk.

A second feature is its effect on the proteins and enzymes that regulate the action of other drugs. Androgens alter the synthesis of blood-clotting factors in the liver, affect insulin sensitivity and fluid balance. Because of this, the doses of some drugs that were adjusted before starting the androgen may become excessive.

A third feature is interaction with corticosteroid metabolism. A laboratory study by Fürstenberger and co-authors (2012) showed that fluoxymesterone inhibits the enzyme 11β-HSD2, which inactivates cortisol in the kidneys. This creates a basis for sodium retention and increased blood pressure, especially in combination with substances that have a similar effect.

Finally, in the sports context the drug is often combined with other substances without medical supervision. Each individual interaction may be moderate, but their sum is unpredictable — which is exactly why self-directed "stacking" is dangerous.

Alcohol and the liver

Alcohol is the most common and probably the most underestimated interaction. Ethanol by itself damages the liver, causing fatty degeneration and inflammation. Oral 17α-alkylated androgens, according to the LiverTox database, are associated with cholestatic injury and, with prolonged use, with peliosis and liver tumors.

There are no direct clinical studies of combining fluoxymesterone with alcohol, but the mechanisms of the two toxic effects differ, and there is no reason to believe they neutralize each other. It is more logical to expect a cumulative burden, especially with regular alcohol consumption.

There is also a behavioral aspect. In some people androgens increase irritability and impulsivity, while alcohol reduces self-control. The Endocrine Society review (Pope et al., 2014) points out that combining anabolic steroids with other psychoactive substances is common and complicates risk assessment.

The practical conclusion is simple: while on any oral androgens, and during the period of normalizing liver values afterward, alcohol is best excluded. The appearance of jaundice, itchy skin, dark urine or pale stools is a reason to see a doctor without delay.

Interactions described in the package insert

The package insert for Halotestin lists several specific interactions of direct clinical significance. The most important concerns oral anticoagulants, particularly warfarin: androgens enhance their action, so with concurrent use the anticoagulant dose may need to be reduced and the INR (international normalized ratio) monitored more often. Underestimating this interaction risks bleeding.

The second interaction concerns patients with diabetes mellitus. Androgens can lower blood glucose, and people receiving insulin or other glucose-lowering drugs may need dose adjustments. Without glucose monitoring this creates a risk of hypoglycemia.

The third is combination with corticosteroids or ACTH, which can worsen edema. Given the aforementioned inhibition of 11β-HSD2, this interaction has a pharmacological explanation. For people with heart, kidney or liver failure, edema can be dangerous.

The insert also mentions that concurrent use of oxyphenbutazone (an anti-inflammatory drug, now rarely used) may raise its blood levels. This interaction is of mainly historical significance, but it shows that androgens can influence the pharmacokinetics of other drugs.

Potential interactions: liver, kidneys, blood pressure

In addition to those described in the insert, there are interactions that follow logically from the drug’s properties. Isotretinoin, often taken for steroid acne, can itself raise liver enzymes and triglycerides. Combining it with an oral androgen that worsens the lipid profile and burdens the liver calls for especially careful monitoring of test results.

Large doses of paracetamol, some antifungal and antituberculosis agents, and numerous "natural" supplements have their own hepatotoxic potential. Each additional substance with such a profile increases the uncertainty about the state of the liver.

Nonsteroidal anti-inflammatory drugs, often taken for joint pain, reduce renal blood flow and promote sodium retention. Combined with androgenic fluid retention and increased blood pressure, this can be an unfavorable combination, especially against a background of dehydration. Diuretics, used before competitions, add the risk of electrolyte disturbances.

Stimulants — caffeine in high doses, synephrine, other "fat burners" — raise blood pressure and heart rate. Combined with an androgen that worsens lipids and can raise blood pressure, this increases the load on the cardiovascular system. Even licorice in large amounts inhibits 11β-HSD2 and could theoretically amplify the corresponding effect of fluoxymesterone.

How to reduce the risk of interactions

The most important tool is full information for the doctor. A person taking warfarin, insulin or other ongoing medications must be sure to tell the doctor about any hormonal drugs, even if they consider them "sports" products that "have nothing to do" with the main treatment.

It is equally important to report fluoxymesterone use with any new prescription — from antibiotics to painkillers. A doctor and pharmacist can assess an interaction only if they know the full list of substances.

Basic safety rules recommended by our editorial team:

• do not combine oral androgens with alcohol;
• do not change the doses of anticoagulants or glucose-lowering drugs on your own — only on a doctor’s decision;
• do not take NSAIDs for long periods or unnecessarily, especially against a background of dehydration;
• have liver panels, a lipid profile, glucose, electrolytes and creatinine tested at intervals determined by your doctor;
• be cautious with "detox" and "hepatoprotective" supplements of unknown composition.

Athletes should also remember that fluoxymesterone is on the WADA Prohibited List in the category of anabolic agents. Any use of it in sport subject to anti-doping control is a violation of the rules.

Editorial conclusions

The fluoxymesterone package insert directly describes interactions with anticoagulants, insulin and glucose-lowering agents, corticosteroids and oxyphenbutazone. The most dangerous of these is the enhancement of warfarin’s action with a risk of bleeding.

Alcohol, isotretinoin and other hepatotoxic substances increase the burden on the liver, while NSAIDs, diuretics and stimulants burden the kidneys and cardiovascular system.

The key to safety is transparency with your doctor and regular laboratory monitoring, not self-directed "stacking".

We also recommend reading our articles on the effect of fluoxymesterone on the kidneys, on liver panels when using oral androgens, and on the cardiovascular risks of halotestin.

References

1. Halotestin (fluoxymesterone tablets, USP). Prescribing information. Pharmacia & Upjohn.
2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Androgenic Steroids. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
3. Fürstenberger C, Vuorinen A, Da Cunha T, et al. The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012;126(2):353–361.
4. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
5. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–554.
6. World Anti-Doping Agency. The World Anti-Doping Code: International Standard — Prohibited List. Montreal: WADA (актуальна редакція).